2 Sympathy Plays To Watch For In Wake Of Biogen's Positive Alzheimer's Drug Data

 The positive results reported by Biogen-Eisai will increase investor focus on near-term anti-amyloid beta monoclonal antibody readouts from Roche AG RHHBY and Eli Lilly & Company LLY, Goodman said in the note.

Roche is evaluating a candidate called gantenerumab in the GRADUATE Phase 3 study. The Swiss pharma giant is expected to read out from the study in the fourth quarter.

Lilly, for its part, will release results from the TRAILBLAZER ALZ-2 study of donanemab, another amyloid-targeting Alzheimer's candidate, in the first half of 2023.

https://www.benzinga.com/general/biotech/22/09/29046138/2-sympathy-plays-to-watch-for-in-the-wake-of-biogens-positive-alzheimers-drug-data